Trial Profile
A Phase II Clinical Trial of Angiotensin 1-7 For the Second or Third Line Treatment of Patients With Metastatic or Unresectable Sarcomas.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Angiotensin-1-7 (Primary)
- Indications Sarcoma
- Focus Adverse reactions; Therapeutic Use
- 25 Mar 2013 Planned End Date changed from 1 Oct 2014 to 1 Oct 2015, as reported by ClinicalTrials.gov.
- 25 Mar 2013 Planned End Date changed from 1 Oct 2014 to 1 Oct 2015, as reported by ClinicalTrials.gov.
- 31 Jan 2013 Planned End Date changed from 1 Oct 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov (NCT00974545).